Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Follow-Up Questions
Qui est le CEO de Vivos Inc ?
Dr. Michael Korenko est le Chief Executive Officer de Vivos Inc, il a rejoint l'entreprise depuis 2009.
Quelle est la performance du prix de l'action RDGL ?
Le prix actuel de RDGL est de $0.0766, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Vivos Inc ?
Vivos Inc appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Vivos Inc ?
La capitalisation boursière actuelle de Vivos Inc est de $34.7M
